

Denmark-Copenhagen: Pharmaceutical products**OJ S 73/2019 12/04/2019****Contract notice****Supplies****Legal Basis:**

Directive 2014/24/EU

Section I: Contracting authority

I.1. Name and addresses

Official name: Amgros I/S

Postal address: Dampfærgevej 22

Town: København Ø

NUTS code: DK0 Danmark

Postal code: 2100

Country: Denmark

Contact person: Flemming Sonne

E-mail: udbud@amgros.dk

Telephone: +45 88713000

Fax: +45 88713008

Internet address(es):Main address: <http://www.amgros.dk>**I.1. Name and addresses**

Official name: Landspítali

Postal address: Eiríksgata 5

Town: Reykjavík

NUTS code: IS Ísland

Postal code: 101

Country: Iceland

Contact person: Hulda Harðardóttir

E-mail: huldahar@landspitali.is**Internet address(es):**Main address: <http://www.rikiskaup.is>**I.1. Name and addresses**

Official name: Sykehusinnkjøp HF, divisjon legemidler

Postal address: Grev Wedels plass 7

Town: Oslo

NUTS code: NO Norge

Postal code: 0151

Country: Norway

Contact person: Eirik Sverrisson

E-mail: eirik.sverrisson@sykehusinnkjop.no**Internet address(es):**Main address: <http://www.sykehusinnkjop.no>**I.2. Information about joint procurement**

The contract involves joint procurement

In the case of joint procurement involving different countries, state applicable national procurement law:

Danish law

I.3. Communication

The procurement documents are available for unrestricted and full direct access, free of charge, at: www.amgros.dk

Additional information can be obtained from the abovementioned address

Tenders or requests to participate must be submitted to the abovementioned address

I.4. Type of the contracting authority

Body governed by public law

I.5. Main activity

Health

Section II: Object

II.1. Scope of the procurement

II.1.1. Title

Joint Nordic Procurement of Pharmaceuticals — 2020 — NF1.620.a

II.1.2. Main CPV code

33600000 Pharmaceutical products

II.1.3. Type of contract

Supplies

II.1.4. Short description

Denmark, Norway and Iceland have entered into cooperation regarding the procurement of pharmaceuticals. The countries will jointly procure and award Framework Agreements in order to ensure the supply of pharmaceuticals to the public hospitals and health authorities in the countries. In Denmark certain pharmaceuticals is resold to the Faroe Island and Greenland. For this procurement group delivery to Iceland is an option, see Section II.2.11).

Tenders for the pharmaceuticals are invited so that the Contracting Authorities can enter into Framework Agreements for delivery of the pharmaceuticals requested in the list of products and specified under the various lots below (Section II.2.4).

The Framework Agreements are non-exclusive to the supplier. The hospitals and health authorities are not obliged to use the Framework Agreement.

II.1.5. Estimated total value

Value excluding VAT: 11 100 000,00 EUR

II.1.6. Information about lots

This contract is divided into lots: yes

Tenders may be submitted for all lots

II.2. Description

II.2.1. Title

1

Lot No: 1

II.2.2. Additional CPV code(s)

33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: DK Danmark

NUTS code: IS Ísland

NUTS code: NO Norge

II.2.4. Description of the procurement

Procurement No: 1

ATC Code: A04AA01

Generic name: Ondansetrone

Pharmaceutical form: Injection Fluid

Strength: 2 mg/ml

Package: 2 ml

Unit value: 16 mg

Volume in units: (Iceland: 1029) (Norway: 50000) (Denmark: 93478).

The above pharmaceuticals are put up for tender independently of the pharmaceuticals under the other procurement numbers.

Each procurement number is considered a separate lot. A supplier may thus choose to submit tender for 1, several or all procurement numbers, and award will take place separately for each individual procurement number. Reference is made to the tender specifications, including the provisions on submission of tender under the individual procurement numbers.

Under the title "quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries.

It should be noted that this estimate is based on historic consumption data and that the suppliers must expect that the actual purchase under a Framework Agreement may differ significantly from the estimate. Reference is made to Paragraph 3.6 of the tender specifications and Clause 2 of the Framework Agreement.

The supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.

Marketing authorisations applicable for Denmark, Norway and Iceland must be in place for the pharmaceuticals in sufficient time to ensure that the pharmaceuticals appear in Medicinpriser. dk (Denmark), "Farmalogg" (Norway) and "Lyfjaverðskrá" (Iceland) no later than 1.12.2019.

The requirement regarding and "Lyfjaverðskrá" (Iceland) only apply if Iceland is part of the Framework Agreement, see Section II.2.11).

II.2.5. Award criteria

Criteria below

Price

II.2.6. Estimated value

Value excluding VAT: 1 050 000,00 EUR

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/02/2020 End: 31/01/2021

This contract is subject to renewal: yes

Description of renewals:

The Contracting Authorities shall be entitled to extend the Framework Agreement up to 2 times for each pharmaceutical on unchanged terms and conditions by up to 6 months.

II.2.10.

Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: yes

Description of options:

Clause 1 of the Framework Agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option for delivery in a post-agreement period (i.e. after the purchase period). The 3 options may be exercised on the terms and conditions stipulated in the Framework Agreement and in the tender specifications.

For this procurement group delivery to Iceland is an option. The supplier can choose to submit a tender for this option. If the supplier is awarded a Framework Agreement, the Framework Agreement will cover delivery of the pharmaceuticals in all 3 countries for the purchase period. If the supplier chooses not to give a tender for the delivery to Iceland the Framework Agreement will cover delivery of the pharmaceuticals in Denmark and Norway.

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information

II.2. Description

II.2.1. Title

2

Lot No: 2

II.2.2. Additional CPV code(s)

33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: DK Danmark

NUTS code: IS Ísland

NUTS code: NO Norge

II.2.4. Description of the procurement

Procurement No: 2

ATC Code: A04AA01

Generic name: Ondansetrone

Pharmaceutical form: Injection Fluid

Strength: 2 mg/ml

Package: 4 ml

Unit value: 16 mg

Volume in units: (Iceland: 329) (Norway: 15000) (Denmark: 16625).

The above pharmaceuticals are put up for tender independently of the pharmaceuticals under the other procurement numbers.

Each procurement number is considered a separate lot. A supplier may thus choose to submit tender for 1, several or all procurement numbers, and award will take place separately for each individual procurement number. Reference is made to the tender specifications, including the provisions on submission of tender under the individual procurement numbers.

Under the title "quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries.

It should be noted that this estimate is based on historic consumption data and that the suppliers must expect that the actual purchase under a Framework Agreement may differ significantly from the estimate. Reference is made to Paragraph 3.6 of the tender specifications and Clause 2 of the Framework Agreement.

The supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.

Marketing authorisations applicable for Denmark, Norway and Iceland must be in place for the pharmaceuticals in sufficient time to ensure that the pharmaceuticals appear in Medicinpriser.dk (Denmark), "Farmalogg" (Norway) and "Lyfjaverðskrá" (Iceland) no later than 1.12.2019.

The requirement regarding "Lyfjaverðskrá" (Iceland) only apply if Iceland is part of the Framework Agreement, see Section II.2.11).

II.2.5. Award criteria

Criteria below

Price

II.2.6. Estimated value

Value excluding VAT: 200 000,00 EUR

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/02/2020 End: 31/01/2021

This contract is subject to renewal: yes

Description of renewals:

The Contracting Authorities shall be entitled to extend the Framework Agreement up to 2 times for each pharmaceutical on unchanged terms and conditions by up to 6 months.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: yes

Description of options:

Clause 1 of the Framework Agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option for delivery in a post-agreement period (i.e. after the purchase period). The 2 options may be exercised on the terms and conditions stipulated in the Framework Agreement and in the tender specifications.

For this procurement group delivery to Iceland is an option. The supplier can choose to submit a tender for this option. If the supplier is awarded a Framework agreement, the Framework Agreement will cover delivery of the pharmaceuticals in all 3 countries for the purchase period. If the supplier chooses not to give a tender for the delivery to Iceland the Framework Agreement will cover delivery of the pharmaceuticals in Denmark and Norway.

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information

II.2. Description

II.2.1. Title

3

Lot No: 3

II.2.2. Additional CPV code(s)

33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: DK Danmark

NUTS code: IS Ísland

NUTS code: NO Norge

II.2.4. Description of the procurement

Procurement No: 3

ATC Code: J01GB03

Generic name: Gentamicin

Pharmaceutical form: Infusion Fluid

Strength: 1 mg/ml

Unit value: 0,24 g

Volume in units: (Iceland: 47) (Norway: 6667) (Denmark: 903)

The above pharmaceuticals are put up for tender independently of the pharmaceuticals under the other procurement numbers.

Each procurement number is considered a separate lot. A supplier may thus choose to submit tender for 1, several or all procurement numbers, and award will take place separately for each individual procurement number. Reference is made to the tender specifications, including the provisions on submission of tender under the individual procurement numbers.

Under the title "quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries.

It should be noted that this estimate is based on historic consumption data and that the suppliers must expect that the actual purchase under a Framework Agreement may differ significantly from the estimate. Reference is made to Paragraph 3.6 of the tender specifications and Clause 2 of the Framework Agreement.

The supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.

Marketing authorisations applicable for Denmark, Norway and Iceland must be in place for the pharmaceuticals in sufficient time to ensure that the pharmaceuticals appear in Medicinpriser.dk (Denmark), "Farmalogg" (Norway) and "Lyfjaverðskrá" (Iceland) no later than 1.12.2019.

The requirement regarding "Lyfjaverðskrá" (Iceland) only apply if Iceland is part of the framework agreement, see Section II.2.11).

II.2.5. Award criteria

Criteria below

Price

II.2.6. Estimated value

Value excluding VAT: 250 000,00 EUR

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/02/2020 End: 31/01/2021

This contract is subject to renewal: yes

Description of renewals:

The Contracting Authorities shall be entitled to extend the Framework Agreement up to 2 times for each pharmaceutical on unchanged terms and conditions by up to 6 months.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: yes

Description of options:

Clause 1 of the Framework Agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option for delivery in a post-agreement period (i.e. after the purchase period). The 2 options may be exercised on the terms and conditions stipulated in the Framework Agreement and in the tender specifications.

For this procurement group delivery to Iceland is an option. The supplier can choose to submit a tender for this option. If the supplier is awarded a Framework Agreement, the Framework Agreement will cover delivery of the pharmaceuticals in all 3 countries for the purchase period. If the supplier chooses not to give a tender for the delivery to Iceland the Framework Agreement will cover delivery of the pharmaceuticals in Denmark and Norway.

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information

II.2. Description

II.2.1. Title

4

Lot No: 4

II.2.2. Additional CPV code(s)

33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: DK Danmark

NUTS code: IS Ísland

NUTS code: NO Norge

II.2.4. Description of the procurement

Procurement No: 4

ATC Code: J01GB03

Generic name: Gentamicin

Pharmaceutical form: Infusion Fluid

Strength: 3 mg/ml

Package: 80 ml

Unit value: 0,24 g

Volume in units: (Iceland: 60) (Norway: 33000) (Denmark: 4750).

The above pharmaceuticals are put up for tender independently of the pharmaceuticals under the other procurement numbers.

Each procurement number is considered a separate lot. A supplier may thus choose to submit tender for 1, several or all procurement numbers, and award will take place separately for each individual procurement number. Reference is made to the tender specifications, including the provisions on submission of tender under the individual procurement numbers.

Under the title "quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries.

It should be noted that this estimate is based on historic consumption data and that the suppliers must expect that the actual purchase under a Framework Agreement may differ

significantly from the estimate. Reference is made to Paragraph 3.6 of the tender specifications and Clause 2 of the Framework Agreement.

The supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.

Marketing authorisations applicable for Denmark, Norway and Iceland must be in place for the pharmaceuticals in sufficient time to ensure that the pharmaceuticals appear in Medicinpriser.dk (Denmark), "Farmalogg" (Norway) and "Lyfjaverðskrá" (Iceland) no later than 1.12.2019.

The requirement regarding "Lyfjaverðskrá" (Iceland) only apply if Iceland is part of the framework agreement, see Section II.2.11).

II.2.5. Award criteria

Criteria below

Price

II.2.6. Estimated value

Value excluding VAT: 1 850 000,00 EUR

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/02/2020 End: 31/01/2021

This contract is subject to renewal: yes

Description of renewals:

The Contracting Authorities shall be entitled to extend the Framework Agreement up to 2 times for each pharmaceutical on unchanged terms and conditions by up to 6 months.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: yes

Description of options:

Clause 1 of the Framework Agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option for delivery in a post-agreement period (i.e. after the purchase period). The 2 options may be exercised on the terms and conditions stipulated in the Framework Agreement and in the tender specifications.

For this procurement group delivery to Iceland is an option. The supplier can choose to submit a tender for this option. If the supplier is awarded a Framework Agreement, the Framework Agreement will cover delivery of the pharmaceuticals in all 3 countries for the purchase period. If the supplier chooses not to give a tender for the delivery to Iceland the Framework Agreement will cover delivery of the pharmaceuticals in Denmark and Norway.

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: no

II.2.14. Additional information

II.2. Description

II.2.1. Title

5

Lot No: 5

II.2.2. Additional CPV code(s)

33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: DK Danmark

NUTS code: IS Ísland

NUTS code: NO Norge

II.2.4. Description of the procurement

Procurement No: 5

ATC Code: J01GB03

Generic name: Gentamicin

Pharmaceutical form: Infusion Fluid

Strength: 3 mg/ml

Package: 120 ml

Unit value: 0,24 g

Volume in units: (Iceland: 64) (Norway: 39000) (Denmark: 17205).

The above pharmaceuticals are put up for tender independently of the pharmaceuticals under the other procurement numbers.

Each procurement number is considered a separate lot. A supplier may thus choose to submit tender for 1, several or all procurement numbers, and award will take place separately for each individual procurement number. Reference is made to the tender specifications, including the provisions on submission of tender under the individual procurement numbers.

Under the title "quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries.

It should be noted that this estimate is based on historic consumption data and that the suppliers must expect that the actual purchase under a Framework Agreement may differ significantly from the estimate. Reference is made to Paragraph 3.6 of the tender specifications and Clause 2 of the Framework Agreement.

The supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.

Marketing authorisations applicable for Denmark, Norway and Iceland must be in place for the pharmaceuticals in sufficient time to ensure that the pharmaceuticals appear in Medicinpriser. dk (Denmark), "Farmalogg" (Norway) and "Lyfjaverðskrá" (Iceland) no later than 1.12.2019.

The requirement regarding "Lyfjaverðskrá" (Iceland) only apply if Iceland is part of the framework agreement, see Section II.2.11).

II.2.5. Award criteria

Criteria below

Price

II.2.6. Estimated value

Value excluding VAT: 500 000,00 EUR

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/02/2020 End: 31/01/2021

This contract is subject to renewal: yes

Description of renewals:

The Contracting Authorities shall be entitled to extend the Framework Agreement up to 2 times for each pharmaceutical on unchanged terms and conditions by up to 6 months.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: yes

Description of options:

Clause 1 of the Framework Agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option for delivery in a post-agreement period (i.e. after the purchase period). The 2 options may be exercised on the terms and conditions stipulated in the framework agreement and in the tender specifications.

For this procurement group delivery to Iceland is an option. The supplier can choose to submit a tender for this option. If the supplier is awarded a Framework Agreement, the Framework Agreement will cover delivery of the pharmaceuticals in all 3 countries for the purchase period. If the supplier chooses not to give a tender for the delivery to Iceland the Framework Agreement will cover delivery of the pharmaceuticals in Denmark and Norway.

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information

II.2. Description

II.2.1. Title

6

Lot No: 6

II.2.2. Additional CPV code(s)

33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: DK Danmark

NUTS code: IS Ísland

NUTS code: NO Norge

II.2.4. Description of the procurement

Procurement No: 6,

ATC Code: N02BE01

Generic name: Paracetamol

Pharmaceutical form: Infusion Fluid

Strength: 10 mg/ml

Package: 10-50 ml

Unit value: 3 g

Volume in units: (Iceland: 1) (Norway: 21667) (Denmark: 1817).

The above pharmaceuticals are put up for tender independently of the pharmaceuticals under the other procurement numbers.

Each procurement number is considered a separate lot. A supplier may thus choose to submit tender for 1, several or all procurement numbers, and award will take place separately for each individual procurement number. Reference is made to the tender specifications, including the provisions on submission of tender under the individual procurement numbers.

Under the title "quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries.

It should be noted that this estimate is based on historic consumption data and that the suppliers must expect that the actual purchase under a Framework Agreement may differ

significantly from the estimate. Reference is made to Paragraph 3.6 of the tender specifications and Clause 2 of the Framework Agreement.

The supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.

Marketing authorisations applicable for Denmark, Norway and Iceland must be in place for the pharmaceuticals in sufficient time to ensure that the pharmaceuticals appear in Medicinpriser.dk (Denmark), "Farmalogg" (Norway) and "Lyfjaverðskrá" (Iceland) no later than 1.12.2019.

The requirement regarding "Lyfjaverðskrá" (Iceland) only apply if Iceland is part of the Framework Agreement, see Section II.2.11).

II.2.5. Award criteria

Criteria below

Price

II.2.6. Estimated value

Value excluding VAT: 4 850 000,00 EUR

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/02/2020 End: 31/01/2021

This contract is subject to renewal: yes

Description of renewals:

The Contracting Authorities shall be entitled to extend the Framework Agreement up to 2 times for each pharmaceutical on unchanged terms and conditions by up to 6 months.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: yes

Description of options:

Clause 1 of the Framework Agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option for delivery in a post-agreement period (i.e. after the purchase period). The 2 options may be exercised on the terms and conditions stipulated in the Framework Agreement and in the tender specifications.

For this procurement group delivery to Iceland is an option. The supplier can choose to submit a tender for this option. If the supplier is awarded a Framework Agreement, the Framework Agreement will cover delivery of the pharmaceuticals in all 3 countries for the purchase period. If the supplier chooses not to give a tender for the delivery to Iceland the Framework Agreement will cover delivery of the pharmaceuticals in Denmark and Norway.

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: no

II.2.14. Additional information

II.2. Description

II.2.1. Title

7

Lot No: 7

II.2.2. Additional CPV code(s)

33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: DK Danmark

NUTS code: IS Ísland

NUTS code: NO Norge

II.2.4. Description of the procurement

Procurement No: 7

ATC Code: N02BE01

Generic name: Paracetamol

Pharmaceutical form: Infusion Fluid

Strength: 10 mg/ml

Package: 100 ml

Unit value: 3 g

Volume in units: (Iceland: 880) (Norway: 21667) (Denmark: 10688).

The above pharmaceuticals are put up for tender independently of the pharmaceuticals under the other procurement numbers.

Each procurement number is considered a separate lot. A supplier may thus choose to submit tender for 1, several or all procurement numbers, and award will take place separately for each individual procurement number. Reference is made to the tender specifications, including the provisions on submission of tender under the individual procurement numbers.

Under the title “quantity in units”, an estimated consumption of the pharmaceuticals is indicated for each of the countries.

It should be noted that this estimate is based on historic consumption data and that the suppliers must expect that the actual purchase under a Framework Agreement may differ significantly from the estimate. Reference is made to Paragraph 3.6 of the tender specifications and Clause 2 of the Framework Agreement.

The supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.

Marketing authorisations applicable for Denmark, Norway and Iceland must be in place for the pharmaceuticals in sufficient time to ensure that the pharmaceuticals appear in Medicinpriser. dk (Denmark), “Farmalogg” (Norway) and “Lyfjaverðskrá” (Iceland) no later than 1.12.2019.

The requirement regarding “Lyfjaverðskrá” (Iceland) only apply if Iceland is part of the Framework Agreement, see Section II.2.11).

II.2.5. Award criteria

Criteria below

Price

II.2.6. Estimated value

Value excluding VAT: 2 400 000,00 EUR

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/02/2020 End: 31/01/2021

This contract is subject to renewal: yes

Description of renewals:

The Contracting Authorities shall be entitled to extend the Framework Agreement up to 2 times for each pharmaceutical on unchanged terms and conditions by up to 6 months.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: yes

Description of options:

Clause 1 of the Framework Agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option for delivery in a post-agreement period (i.e. after the purchase period). The 2 options may be exercised on the terms and conditions stipulated in the Framework Agreement and in the tender specifications.

For this procurement group delivery to Iceland is an option. The supplier can choose to submit a tender for this option. If the supplier is awarded a Framework Agreement, the Framework Agreement will cover delivery of the pharmaceuticals in all 3 countries for the purchase period. If the supplier chooses not to give a tender for the delivery to Iceland the Framework Agreement will cover delivery of the pharmaceuticals in Denmark and Norway.

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information

Section III: Legal, economic, financial and technical information

III.1. Conditions for participation

III.1.1. Suitability to pursue the professional activity, including requirements relating to enrolment on professional or trade registers

List and brief description of conditions:

Suppliers wishing to submit tender must use the standard form of the European Single Procurement Document (ESPD) for the declaration regarding the compulsory grounds for exclusion set out in Sections 135-136 of the Danish Public Procurement Act (udbudsloven) (Act No 1564 of 15.12.2015 as amended). Further information on the completion and application of the ESPD in the tender process is available in the guide drawn up by Amgros in this respect and in the "Instructions for the European Single Procurement Document" drawn up by the Danish Competition and Consumer Authority (Konkurrence- og Forbrugerstyrelsen). The successful tenderer(s) to whom the Contracting Authorities intends to award the Framework Agreement must also, before the award, provide documentation to the Contracting Authorities regarding the absence of compulsory grounds for exclusion as set out in Sections 152-153 of the Public Procurement Act. The Contracting Authorities is not entitled to exclude a supplier who is subject to 1 or more of the mandatory exclusion grounds set out in Sections 135-136 of the Public Procurement Act if the supplier has provided sufficient documentation that the supplier is reliable, even if the supplier is subject to 1 or more of the grounds for exclusion set out in Section 138 of the Public Procurement Act. The Contracting Authorities reserves the right to carry out a so-called "self-cleaning" process if relevant.

III.1.2. Economic and financial standing

List and brief description of selection criteria:

No information required.

III.1.3. Technical and professional ability

List and brief description of selection criteria:

No information required.

III.2. Conditions related to the contract

III.2.2. Contract performance conditions

Reference is made to the provisions of the draft Framework Agreement and Section II.2.4). No specific legal form is required. If the contract is awarded to a group of suppliers, each participant must undertake joint and several liability and appoint a joint representative.

Section IV: Procedure

IV.1. Description

IV.1.1. Type of procedure

Open procedure

IV.1.3. Information about a framework agreement or a dynamic purchasing system

The procurement involves the establishment of a framework agreement
Framework agreement with a single operator

IV.1.8. Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: yes

IV.2. Administrative information

IV.2.2. Time limit for receipt of tenders or requests to participate

Date: 21/05/2019 Local time: 12:00

IV.2.3. Estimated date of dispatch of invitations to tender or to participate to selected candidates

IV.2.4. Languages in which tenders or requests to participate may be submitted

Danish, Norwegian, Swedish, English

IV.2.7. Conditions for opening of tenders

Date: 21/05/2019 Local time: 12:00

Place:

Amgros I/S, Dampfærgevej 27-29, DK-2100 Copenhagen Ø.

Information about authorised persons and opening procedure: The tenderers are not permitted to attend the opening of the tenders. Tenders will be registered upon receipt, and tenders received on time will be opened collectively after expiry of the deadline for submission of tenders.

Section VI: Complementary information

VI.1. Information about recurrence

This is a recurrent procurement: no

VI.2. Information about electronic workflows

Electronic ordering will be used

Electronic invoicing will be accepted

VI.3. Additional information

This call for tenders is conducted as an open procedure in accordance with the Danish Procurement Act (udbudsloven). The procurement procedure is subject to Danish law and any complaints of the procurement procedure shall be lodged with the Danish Complaints Board for Public Procurement (Klagenævnet for udbud), see Section VI.4.3).

In relation to Section II.2.4) it should be noted that the Contracting Authorities has considered whether the procurement group can be further subdivided. The Contracting Authorities has assessed that this is not the case on the basis of considerations of economies of scale which will not be realisable in case of a further subdivision, as well as costs and patient safety considerations related to the subsequent management of contract and pharmaceuticals. In relation to Sections II.1.5) and II.2.6) it should be noted that the estimated value indicated in Section II.1.5) is the total estimated value of all procurement numbers (lots) for the duration of the Framework Agreement, including the option of renewal, see Section II.2.7). Section II.2.6) sets out the estimated value for each procurement number, including the option of renewal, see Section II.2.7). The value is based on the AIP ("Apotekernes Indkøbspris" published by the Danish Medicines Agency) of the pharmaceuticals. It should furthermore be noted that the estimated value is based on historic consumption data and that the actual purchase under a Framework Agreement may differ significantly from the estimate, see Section II.2.4), Paragraph 3.6 of the tender specifications and Clause 2 of the Framework Agreement. Questions concerning the tender documents must be submitted through the tendering system, see the provisions of the tender specifications in this regard. The access to submit tender requires that the operator is registered as a user of Amgros' tendering system. The registration as a user may take a few days, and the tenderer must therefore make sure to register in good time. Reference is made to the information provided in the tendering system, including the user guide. In relation to Section VI.2) it should be noted that electronic invoicing is required.

VI.4. Procedures for review

VI.4.1. Review body

Official name: Klagenævnet for Udbud

Postal address: Nævnenes Hus, Toldboden 2

Town: Viborg

Postal code: 8800

Country: Denmark

E-mail: klfu@erst.dk

Telephone: +45 35291095

Internet address: <https://erhvervsstyrelsen.dk/klagenaevnet-for-udbud>

VI.4.3. Review procedure

Precise information on deadline(s) for review procedures:

Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act No 593 of 2.6.2016 as amended) the following deadlines apply to the lodging of complaints:

Complaints of the tendering procedure must be lodged with the Complaints Board for Public Procurement within 6 months after the contracting entity has entered into a Framework Agreement calculated from the day after the day when the contracting entity has notified the affected applicants and tenderers, see Section 7(2), Para. (3) of the Act. Not later than at the time of lodging a complaint with the Danish Complaints Board for Public Procurement, the complainant must notify the contracting authorities in writing that a complaint has been lodged with the Danish Complaints Board for Public Procurement and whether the complaint was lodged during the standstill period, see Section 6(4) of the Act. In cases where the complaint was not lodged within the standstill period, the complainant must furthermore indicate whether a suspensory effect of the complaint has been requested, see clause 6(4) of the Act.

VI.4.4. Service from which information about the review procedure may be obtained

Official name: Konkurrence- og Forbrugerstyrelsen

Postal address: Carl Jacobsens vej 35
Town: Valby
Postal code: 2500
Country: Denmark
Telephone: +45 41715000
Internet address: <http://www.kfst.dk>

VI.5. Date of dispatch of this notice

08/04/2019